EUVIMEDEUVIMED entdecken
VergleichsstudieMultizentrische StudieOpen Access · CC BY 4.0

Mismatched related donor allogeneic haematopoietic cell transplantation compared to other donor types for Ph+ chronic myeloid leukaemia: A retrospective analysis from the Chronic Malignancies Working Party of the EBMT

Francesco Onida iD, Luuk Gras, Junran Ge, Linda Koster, Rose-Marie Hamladji, Jenny Byrne, Daniele Avenoso, Mahmoud Aljurf, Marie Robin iD, Kazimierz Halaburda, Jakob Passweg, Urpu Salmenniemi und 18 weitere

British Journal of Haematology · 2024

DOI: 10.1111/bjh.19448 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift British Journal of Haematology, 2024. Verfasst von Francesco Onida und 29 weiteren Autor:innen. Beteiligte Einrichtung: Hematology-BMT Centre, ASST Fatebenefratelli-Sacco, University of Milan, Milan, Italy. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Leukemia, Myelogenous, Chronic, BCR-ABL Positive. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Allogeneic haematopoietic cell transplantation (allo‐HCT) remains an option for tyrosine kinase inhibitor‐resistant chronic myeloid leukaemia (CML) in first chronic phase (CP1) and high‐risk patients with advanced disease phases. In this European Society for Blood and Marrow Transplantation (EBMT) registry‐based study of 1686 CML patients undergoing first allo‐HCT between 2012 and 2019, outcomes were evaluated according to donor type, particularly focusing on mismatched related donors (MMRDs). Median age at allo‐HCT was 46 years (IQR 36–55). Disease status was CP1 in 43%, second CP (CP2) or later in 27%, accelerated phase in 12% and blast crisis in 18%. Donor type was matched related (MRD) in 39.2%, MMRD in 8.1%, matched unrelated (MUD) in 40.2%, and mismatched unrelated (MMUD) in 12.6%. In 4 years, overall survival (OS) for MRD, MMRD, MUD and MMUD was 61%, 56%, 63% and 59% ( p = 0.21); relapse‐free survival (RFS) was 48%, 42%, 52% and 46% ( p = 0.03); cumulative incidence of relapse (CIR) was 33%, 37%, 27% and 30% ( p = 0.07); non‐relapse mortality (NRM) was 19%, 21%, 21% and 24% ( p = 0.21); and graft‐versus‐host disease (GvHD)‐free/relapse‐free survival (GRFS) was 16%, 18%, 22% and 15% ( p = 0.05) respectively. On multivariate analysis, MMRD use associated with longer engraftment times and higher risk of graft failure compared to MRD or MUD. There was no statistical evidence that MMRD use associated with different OS, RFS and incidence of GvHD compared to other donor types.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationLeukemia, Myelogenous, Chronic, BCR-ABL PositiveHumansMiddle AgedAdultMaleFemaleRetrospective StudiesGraft vs Host DiseaseTransplantation, HomologousRegistriesTissue DonorsUnrelated Donors

Stichwörter der Autor:innen

TKI resistanceallogeneic haematopoietic cell transplantchronic myeloid leukaemiacyclophosphamidehaploidentical donormismatched related donorpost‐transplant

Autor:innen und Institutionen

  • Hematology-BMT Centre, ASST Fatebenefratelli-Sacco, University of Milan, Milan, Italy.
  • EBMT Statistical Unit, Leiden, The Netherlands.
  • EBMT Leiden Study Unit, Leiden, The Netherlands.
  • Centre Pierre et Marie Curie, Alger, Algeria.
  • Nottingham University Hospital, Nottingham, UK.
  • Kings College Hospital, London, UK.

ORCID-Profile: Francesco Onida, Marie Robin, Andrew Clark, Francesca Kinsella, Arnold Ganser, Patrick J Hayden, Donal P McLornan

Zitieren

APA

Onida, F., Gras, L., Ge, J., Koster, L., Hamladji, R. M., Byrne, J., Avenoso, D., Aljurf, M., Robin, M., Halaburda, K., Passweg, J., Salmenniemi, U., Sengeloev, H., Apperley, J., Clark, A., Reményi, P., Morozova, E., Kinsella, F., Lenhoff, S., …, & Chalandon, Y. (2024). Mismatched related donor allogeneic haematopoietic cell transplantation compared to other donor types for Ph+ chronic myeloid leukaemia: A retrospective analysis from the Chronic Malignancies Working Party of the EBMT. British Journal of Haematology. https://doi.org/10.1111/bjh.19448

Vancouver

Onida F, Gras L, Ge J, Koster L, Hamladji RM, Byrne J, et al. Mismatched related donor allogeneic haematopoietic cell transplantation compared to other donor types for Ph+ chronic myeloid leukaemia: A retrospective analysis from the Chronic Malignancies Working Party of the EBMT. British Journal of Haematology. 2024. doi:10.1111/bjh.19448

BibTeX
@article{Onida2024,
  author = {Onida, Francesco and Gras, Luuk and Ge, Junran and Koster, Linda and Hamladji, Rose-Marie and Byrne, Jenny and Avenoso, Daniele and Aljurf, Mahmoud and Robin, Marie and Halaburda, Kazimierz and Passweg, Jakob and Salmenniemi, Urpu and Sengeloev, Henrik and Apperley, Jane and Clark, Andrew and Reményi, Péter and Morozova, Elena and Kinsella, Francesca and Lenhoff, Stig and Ganser, Arnold and Wu, Ka Lung and Perez-Martinez, Antonio and Hayden, Patrick J and Raj, Kavita and Drozd-Sokolowska, Joanna and OrtÍ, Guillermo and de Lavallade, Hugues and Yakoub-Agha, Ibrahim and McLornan, Donal P and Chalandon, Yves},
  title = {Mismatched related donor allogeneic haematopoietic cell transplantation compared to other donor types for Ph+ chronic myeloid leukaemia: A retrospective analysis from the Chronic Malignancies Working Party of the EBMT},
  journal = {British Journal of Haematology},
  year = {2024},
  doi = {10.1111/bjh.19448}
}
Kostenlos starten →